Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-875-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.74 million
Profitability
Miscellaneous
Employees104
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How were Fate Therapeutics' earnings last quarter?
Fate Therapeutics Inc (NASDAQ:FATE) issued its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.04. The biopharmaceutical company had revenue of $2.80 million for the quarter, compared to analyst estimates of $1.09 million. Fate Therapeutics had a negative return on equity of 50.05% and a negative net margin of 934.70%. The business's quarterly revenue was up 180.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.37) EPS. View Fate Therapeutics' Earnings History.
When is Fate Therapeutics' next earnings date?
What price target have analysts set for FATE?
16 Wall Street analysts have issued 12 month target prices for Fate Therapeutics' stock. Their predictions range from $17.00 to $32.00. On average, they expect Fate Therapeutics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 68.9% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.
What is the consensus analysts' recommendation for Fate Therapeutics?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.
Has Fate Therapeutics been receiving favorable news coverage?
Headlines about FATE stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Fate Therapeutics earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Fate Therapeutics.
Who are some of Fate Therapeutics' key competitors?
Some companies that are related to Fate Therapeutics include BioNTech (BNTX), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC) and Editas Medicine (EDIT).
What other stocks do shareholders of Fate Therapeutics own?
Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the folowing people:
- J. Scott Wolchko, President, Chief Executive Officer & Director
- Daniel D. Shoemaker, Chief Scientific Officer
- Yu Waye Chu, Vice President-Clinical Development
- Jim Beitel, Senior Vice President-Corporate Development
- Bahram Valamehr, Chief Development Officer
Who are Fate Therapeutics' major shareholders?
Fate Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include State of New Jersey Common Pension Fund D (0.16%) and Rhumbline Advisers (0.12%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.
Which major investors are buying Fate Therapeutics stock?
How do I buy shares of Fate Therapeutics?
Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Fate Therapeutics' stock price today?
One share of FATE stock can currently be purchased for approximately $14.80.
How big of a company is Fate Therapeutics?
Fate Therapeutics has a market capitalization of $967.71 million and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.
What is Fate Therapeutics' official website?
How can I contact Fate Therapeutics?
Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]
MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
